3 mg [14C]-A4250 capsule ( DrugBank: - )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	1
297	Alagille syndrome	1
338	Progressive familial intrahepatic cholestasis	1

93. Primary biliary cholangitis

---

Clinical trials : 298 /  Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

297. Alagille syndrome

---

Clinical trials : 45 /  Drugs : 21 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

338. Progressive familial intrahepatic cholestasis

---

Clinical trials : 60 /  Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom